Antibody specialist Genmab has continued its shift from out-licensing drugs to developing its own medicines with a deal to buy Merus and its lead drug candidate for head and neck cancer for around $8 ...

Perhaps it's folly to read too much into one Sunday, but the apparent problems of the Eagles and Chiefs don't seem so major anymore. Two prominent coaches got payback against their former teams Sunday ...